Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Market price (% of par)
-
165.84%
-
Total 13F principal
-
$242,680,000
-
Principal change
-
-$1,500,000
-
Total reported market value
-
$402,344,000
-
Number of holders
-
25
-
Value change
-
+$4,745,433
-
Number of buys
-
14
-
Number of sells
-
9
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q2 2017
As of 30 Jun 2017,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 was held by
25 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$242,680,000
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, CQS Cayman LP, WELLS FARGO & COMPANY/MN, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Calamos Advisors LLC, BASSO CAPITAL MANAGEMENT, L.P., Mint Tower Capital Management B.V., CSS LLC/IL, and ANGELO GORDON & CO., L.P..
This page lists
25
institutional bondholders reporting positions
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.